logo
Plus   Neg
Share
Email

Regeneron & Sanofi: Dupixent Approved For Severe Asthma Indication In EU

Dupixent, which is being developed jointly by Regeneron and Sanofi, is now approved in the European Union for use in adults and adolescents 12 years and older as an add-on maintenance treatment for severe asthma with type 2 inflammation. Dupixent is also approved in the EU for the treatment of adults with moderate-to-severe atopic dermatitis.

Dupixent was approved last year in the U.S. as an add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Toyota Motor Corp. (TM) announced plans to invest $391 million at its pickup truck assembly plant in San Antonio, Texas. The investment is part of the Japanese automaker's plan to invest $13 billion in its U.S. operations over five years through 2021. The company said the investment will be used... Virgin Atlantic is set to challenge British Airways' dominance at London Heathrow as the carrier announced plans to fly to 84 new destinations from the airport when its third runway is opened. Chief Executive Shai Weiss said, "Heathrow has been dominated by one airline group for far too long. The... Walmart (WMT) on Wednesday announced that it is teaming up with Capital One to roll out two new credit cards designed to compete with cards from Apple and Amazon. The companies said the Capital One Walmart Rewards Credit Card Program with two new cards will launch on September 24. The program's Mastercard...
Follow RTT